Advertisement
Mayo Clinic Proceedings Home

Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma

      OBJECTIVE

      To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma.

      PATIENTS AND METHODS

      From March 2004 through October 2004, 34 patients were registered for the study. They were treated with 25 mg/d of lenalidomide on days 1 through 21 of a 28-day cycle and 40 mg/d of dexamethasone on days 1 through 4, 9 through 12, and 17 through 20 of each cycle. After 4 cycles of therapy, patients were allowed to discontinue treatment to pursue autologous stem cell transplant (SCT). Treatment beyond 4 cycles was permitted at the physician s discretion.

      RESULTS

      Thirteen patients proceeded to SCT after initial therapy and were censored at that time point for purposes of calculation of response. Thirty-one patients achieved an objective response, defined as a partial response or better (91%; 95% confidence interval, 79%-98%), with a complete response plus very good partial response rate of 56%. The complete response plus very good partial response among the 21 patients who received Rev-Dex without SCT was 67%. The 2-year progression-free survival rates for patients proceeding to SCT and patients remaining on Rev-Dex were 83% and 59%, respectively; the OS rates were 92% and 90% at 2 years and 92% and 85% at 3 years, respectively. The 3-year OS rate for the whole cohort was 88%.

      CONCLUSION

      The Rev-Dex regimen is highly active in the treatment of newly diagnosed multiple myeloma. Responses are durable with a low progression rate at 2 years. Randomized trials that incorporate quality-of-life measures are needed to determine if this and other combination regimens are better used early in therapy or should be reserved for later interventions.
      CI (confidence interval), CR (complete response), ECOG (Eastern Cooperative Oncology Group), G-CSF (granulocyte colony-stimulating factor), OS (overall survival), PFS (progression-free survival), PR (partial response), Rev-Dex (lenalidomide and dexamethasone), SCT (stem cell transplant), Thal-Dex (thalidomide plus dexamethasone), TTP (time to progression), VGPR (very good partial response)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Attal M
        • Harousseau JL
        • Stoppa AM
        • Intergroupe Francais du Myelome
        • et al.
        A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.
        N Engl J Med. 1996; 335: 91-97
        • Child JA
        • Morgan GJ
        • Davies FE
        • Medical Research Council Adult Leukaemia Working Party
        • et al.
        High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
        N Engl J Med. 2003; 348: 1875-1883
        • Alexanian R
        • Barlogie B
        • Tucker S
        VAD-based regimens as primary treatment for multiple myeloma.
        Am J Hematol. 1990; 33: 86-89
        • Kyle RA
        • Rajkumar SV
        Multiple myeloma [published correction appears in N Engl J Med. 2005;352(11)1163].
        N Engl J Med. 2004; 351: 1860-1873
        • Sirohi B
        • Powles R
        Multiple myeloma.
        Lancet. 2004; 363: 875-887
        • Rajkumar SV
        • Hayman S
        • Gertz MA
        • et al.
        Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
        J Clin Oncol. 2002; 20: 4319-4323
        • Wang M
        • Weber DM
        • Delasalle K
        • Alexanian R
        Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
        Am J Hematol. 2005; 79: 194-197
        • Cavo M
        • Zamagni E
        • Tosi P
        • et al.
        First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
        Haematologica. 2004; 89: 826-831
        • Cavo M
        • Zamagni E
        • Tosi P
        • Writing Committee of the Bologna 2002 Study
        • et al.
        Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
        Blood. 2005 Jul 1; 106 (Epub 2005 Mar 10.): 35-39
        • Rajkumar SV
        • Blood E
        • Vesole D
        • Fonseca R
        • Greipp PR
        Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
        J Clin Oncol. 2006 Jan 20; 24 (Epub 2005 Dec 19.): 431-436
        • Hideshima T
        • Chauhan D
        • Shima Y
        • et al.
        Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
        Blood. 2000; 96: 2943-2950
        • Richardson PG
        • Schlossman RL
        • Hideshima T
        • et al.
        A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).
        Blood. 2001; 98 (Abstract 3225.): 775a
        • Richardson PG
        • Schlossman RL
        • Weller E
        • et al.
        Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
        Blood. 2002; 100: 3063-3067
        • Zangari M
        • Tricot G
        • Zeldis J
        • et al.
        Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT).
        Blood. 2001; (Abstract 3226.): 775a
        • Richardson PG
        • Blood E
        • Mitsiades CS
        • et al.
        A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
        Blood. 2006 Nov 15; 108 (Epub 2006 Jul 13.): 3458-3464
        • Bennett CL
        • Angelotta C
        • Yarnold PR
        • et al.
        Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. [letter].
        JAMA. 2006; 296: 2558-2560
        • Rajkumar SV
        • Blood E
        Lenalidomide and venous thrombosis in multiple myeloma. [letter].
        N Engl J Med. 2006; 354: 2079-2080
        • Rajkumar SV
        • Hayman SR
        • Lacy MQ
        • et al.
        Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
        Blood. 2005 Dec 15; 106 (Epub 2005 Aug 23.): 4050-4053
        • Bladé J
        • Samson D
        • Reece D
        • Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant), Chronic Leukaemia Working Party, Myeloma Working Committee of the IBMTR (International Bone Marrow Transplant Registry), ABMTR (Autologous Blood and Marrow Transplant Registry)
        • et al.
        Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.
        Br J Haematol. 1998; 102: 1115-1123
        • Durie BGM
        • Harousseau J-L
        • Miguel JS
        • International Myeloma Working Group
        • et al.
        International uniform response criteria for multiple myeloma [published corrections appear in Leukemia 2006;20(12):2220, Leukemia 2007;21(5):1134].
        Leukemia. 2006 Sep 20; (Epub 2006 Jul 20.): 1467-1473
        • Attal M
        • Harousseau JL
        • Facon T
        • Intergroupe Francophone du Myélome
        • et al.
        Single versus double autologous stem-cell transplantation for multiple myeloma.
        N Engl J Med. 2003; 349: 2495-2502
        • Jagannath S
        • Durie BG
        • Wolf J
        • et al.
        Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
        Br J Haematol. 2005; 129: 776-783
        • Jagannath S
        • Richardson PG
        • Barlogie B
        • SUMMIT/CREST Investigators
        • et al.
        Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
        Haematologica. 2006; 91: 929-934
        • Chanan-Khan A
        • Miller KC
        Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. [letter].
        Leuk Lymphoma. 2005; 46: 1103-1104
        • Oakervee HE
        • Popat R
        • Curry N
        • et al.
        PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
        Br J Haematol. 2005; 129: 755-762
        • Rajkumar SV
        • Jacobus S
        • Callander N
        • Fonseca R
        • Vesole D
        • Greipp P
        A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group.
        Blood. 2006; 108 (Abstract 799.): 239a